Lexicon Pharma (LXRX) Reports In-Line Q1 EPS
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.25 -5.46%
Revenue Growth %: -86.1%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
HYFT, ESBS, PFBK, More
Revenue Growth %: -86.1%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
HYFT, ESBS, PFBK, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $1.13 million versus the consensus estimate of $1.37 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wex, Inc. (WEX) Tops Q2 EPS by 29c; raises guidance
- NVE Corp (NVEC) Tops Q1 EPS by 132c
- MindWalk (HYFT) Misses Q4 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
